EP1068172A4 - HEMMUNG DER BLUTPLÄTTCHENAGGREGATION DURCH NIEDERMOLEKULARGEWICHTIGES HEPARIN IN VERBINDUNG MIT EINEM GP IIb/IIIa ANTAGONISTEN - Google Patents

HEMMUNG DER BLUTPLÄTTCHENAGGREGATION DURCH NIEDERMOLEKULARGEWICHTIGES HEPARIN IN VERBINDUNG MIT EINEM GP IIb/IIIa ANTAGONISTEN

Info

Publication number
EP1068172A4
EP1068172A4 EP99903499A EP99903499A EP1068172A4 EP 1068172 A4 EP1068172 A4 EP 1068172A4 EP 99903499 A EP99903499 A EP 99903499A EP 99903499 A EP99903499 A EP 99903499A EP 1068172 A4 EP1068172 A4 EP 1068172A4
Authority
EP
European Patent Office
Prior art keywords
iib
combination
molecular weight
low molecular
platelet aggregation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99903499A
Other languages
English (en)
French (fr)
Other versions
EP1068172A1 (de
Inventor
Jacquelynn J Cook
Robert J Gould
Frederic L Sax
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Correvio LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9809793.4A external-priority patent/GB9809793D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1068172A1 publication Critical patent/EP1068172A1/de
Publication of EP1068172A4 publication Critical patent/EP1068172A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
EP99903499A 1998-02-02 1999-01-29 HEMMUNG DER BLUTPLÄTTCHENAGGREGATION DURCH NIEDERMOLEKULARGEWICHTIGES HEPARIN IN VERBINDUNG MIT EINEM GP IIb/IIIa ANTAGONISTEN Withdrawn EP1068172A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7342698P 1998-02-02 1998-02-02
US73426P 1998-02-02
GBGB9809793.4A GB9809793D0 (en) 1998-05-07 1998-05-07 Platelet aggregation inhibition
GB9809793 1998-05-07
PCT/US1999/002035 WO1999038827A1 (en) 1998-02-02 1999-01-29 PLATELET AGGREGATION INHIBITION USING LOW MOLECULAR WEIGHT HEPARIN IN COMBINATION WITH A GP IIb/IIIa ANTAGONIST

Publications (2)

Publication Number Publication Date
EP1068172A1 EP1068172A1 (de) 2001-01-17
EP1068172A4 true EP1068172A4 (de) 2006-09-27

Family

ID=26313621

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99903499A Withdrawn EP1068172A4 (de) 1998-02-02 1999-01-29 HEMMUNG DER BLUTPLÄTTCHENAGGREGATION DURCH NIEDERMOLEKULARGEWICHTIGES HEPARIN IN VERBINDUNG MIT EINEM GP IIb/IIIa ANTAGONISTEN

Country Status (5)

Country Link
EP (1) EP1068172A4 (de)
JP (1) JP2002501936A (de)
AU (1) AU740941B2 (de)
CA (1) CA2318215A1 (de)
WO (1) WO1999038827A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794412B1 (en) 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
JP2003526617A (ja) 1999-03-11 2003-09-09 デュポン ファーマシューティカルズ カンパニー 種々の血栓塞栓性障害の予防および治療のための併用療法を提供する低分子量へパリンと血小板凝集阻害剤との相乗効果
WO2000053264A1 (en) * 1999-03-11 2000-09-14 Du Pont Pharmaceuticals Company Treatment of thrombosis by combined use of a factor xa inhibitor and aspirin, tissue plasminogen activator (tpa), a gpiib/iiia antagonist, low molecular weight heparin or heparin
US6518244B2 (en) 2000-03-09 2003-02-11 Intimax Corporation Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof
US6489311B1 (en) * 2000-05-02 2002-12-03 Charlotte-Mecklenburg Hospital Authoirty Method for the prevention of apoptosis
US6770660B2 (en) 2002-05-06 2004-08-03 Artery Llc Method for inhibiting platelet aggregation
EP1574516A1 (de) * 2004-03-05 2005-09-14 Sanofi-Aventis Antithrombotische Verbindungen
US20050261241A1 (en) 2004-05-19 2005-11-24 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
US20090111769A1 (en) * 2005-10-10 2009-04-30 De Kort Martin Antithrombotic Compound
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN112569184A (zh) * 2020-12-30 2021-03-30 山东裕欣药业有限公司 一种盐酸替罗非班注射液及制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035579A1 (en) * 1996-03-27 1997-10-02 Merck & Co., Inc. A method for inhibiting clot formation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4533549A (en) * 1983-01-04 1985-08-06 Lasker Sigmund E Antithrombotic agent
PH25458A (en) * 1987-08-24 1991-07-01 Eisai Co Ltd Piperidine derivatives, therapeutic, preventive agents
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
US5763427A (en) * 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035579A1 (en) * 1996-03-27 1997-10-02 Merck & Co., Inc. A method for inhibiting clot formation

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BRIEGER D B ET AL: "Low molecular weight heparins: Promising therapy for unstable angina and non-Q wave myocardial infarction", THE ASIA PACIFIC HEART JOURNAL, ELSEVIER, vol. 6, no. 3, December 1997 (1997-12-01), pages 173 - 177, XP004886318, ISSN: 1328-0163 *
HABIS M ET AL: "LES ANTITHROMBOTIQUES DE L'ANGOR INSTABLE BILAN DES ESSAIS CLINIQUES", ANNALES DE CARDIOLOGIE ET D'ANGEIOLOGIE, PARIS, FR, vol. 47, no. 1, January 1998 (1998-01-01), pages 22 - 31, XP000933774, ISSN: 0003-3928 *
LANDZBERG B R ET AL: "Pathophysiology and pharmacological approaches for prevention of coronary artery restenosis following coronary artery balloon angioplasty and related procedures", PROGRESS IN CARDIOVASCULAR DISEASES, SAUNDERS, PHILADELPHIA, PA, US, vol. 39, no. 4, January 1997 (1997-01-01), pages 361 - 398, XP004880662, ISSN: 0033-0620 *
LEFKOVITS J ET AL: "Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention", PROGRESS IN CARDIOVASCULAR DISEASES, SAUNDERS, PHILADELPHIA, PA, US, vol. 40, no. 2, September 1997 (1997-09-01), pages 141 - 158, XP004879774, ISSN: 0033-0620 *
MONTALESCOT ET AL: "Les nouveaux antithrombotiques en pathologie coronaire", REVUE DE MEDECINE INTERNE, CMR, ASNIERES, FR, vol. 18, no. 6, June 1997 (1997-06-01), pages 450 - 459, XP005271889, ISSN: 0248-8663 *
SCHUSSHEIM A E ET AL: "Thrombosis, antithrombotic agents, and the antithrombotic approach in cardiac disease", PROGRESS IN CARDIOVASCULAR DISEASES, SAUNDERS, PHILADELPHIA, PA, US, vol. 40, no. 3, November 1997 (1997-11-01), pages 205 - 238, XP004880642, ISSN: 0033-0620 *
See also references of WO9938827A1 *
YARYURA R; DOUCET J; MATHUR V S: "LOW-MOLECULAR-WEIGHT HEPARIN AND ABCIXIMAB FOR THROMBO-OCCLUSIVE SAPHENOUS VEIN GRAFT DISEASE REPORT OF 2 CASES", TEXAS HEART INSTITUTE JOURNAL, vol. 24, 1997, pages 379 - 383, XP000933771 *

Also Published As

Publication number Publication date
EP1068172A1 (de) 2001-01-17
CA2318215A1 (en) 1999-08-05
JP2002501936A (ja) 2002-01-22
AU740941B2 (en) 2001-11-15
WO1999038827A1 (en) 1999-08-05
AU2350699A (en) 1999-08-16

Similar Documents

Publication Publication Date Title
ZA200007359B (en) Laminate having barrier properties.
EP1068172A4 (de) HEMMUNG DER BLUTPLÄTTCHENAGGREGATION DURCH NIEDERMOLEKULARGEWICHTIGES HEPARIN IN VERBINDUNG MIT EINEM GP IIb/IIIa ANTAGONISTEN
EP1250267A4 (de) Wiederverschliesbare verpackung mit barriere-eigenschaften
EP1175157A4 (de) Polymannuronat von niedrigem molekulargewicht
EP1078190A4 (de) Schweres bohrrohr
EP1196283A4 (de) Sperrlaminat
PL346542A1 (en) Imidazo[4,5-c-]-pyridine-4-one derivatives with factor xa inhibiting effect
GB2334574B (en) Improvements in/or relating to the detection of counterfeit items
EP1129371A4 (de) Rückreflektierender artikel
IT1288713B1 (it) Fucani a basso peso molecolare aventi attivita' anticoagulante antitrombinica e antitrombotica
AU2001283150A1 (en) A low molecular weight engineering thermoplastic polyurethane and blends thereof
DE69914181D1 (de) Verpackungslaminat mit wellenförmiger schicht
AU2202397A (en) Iib/iiia antagonists co-administered with aspirin and/or heparin
ATE280558T1 (de) Absorbierende artikel mit verbesserten verteilungseigenschaften bei untersättigung
IL146755A0 (en) Tricyclic analgesics
GB2345080B (en) Multi-purpose barrier
AU4818399A (en) Machine direction oriented high molecular weight, high density polyethylene films with enhanced water vapor transmission properties
GB0307778D0 (en) Improvements in fluid containers
GB9903039D0 (en) Improvements in or relating to a lock guard
TW488324U (en) Fruit grade sorting system using weight with multiple levels
GB9816149D0 (en) Laminated card articles
GB9903466D0 (en) Improvements in or relating to kegs,containers or the like
GB2365959B (en) Improvements in traffic indicator systems
GB9920497D0 (en) A jog trouser/trouser with a pouch pocket
GB0106202D0 (en) Olefinic polymers with enhanced anti-static properties

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000904

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20000904;LT PAYMENT 20000904;LV PAYMENT 20000904;MK PAYMENT 20000904;RO PAYMENT 20000904;SI PAYMENT 20000904

A4 Supplementary search report drawn up and despatched

Effective date: 20060824

17Q First examination report despatched

Effective date: 20061212

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MERCK SHARP & DOHME CORP.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: IROKO CARDIO LLC

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CORREVIO LLC

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4465 20060101AFI20150929BHEP

Ipc: A61K 45/06 20060101ALI20150929BHEP

Ipc: A61P 9/10 20060101ALI20150929BHEP

Ipc: A61K 31/616 20060101ALI20150929BHEP

Ipc: A61K 31/727 20060101ALI20150929BHEP

INTG Intention to grant announced

Effective date: 20151027

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160308